Hopstem Biotechnology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Hopstem Biotechnology is a pioneering cell therapy company leveraging human iPSC technology to create neural progenitor cells for treating central nervous system injuries and diseases. The company has achieved significant regulatory milestones, with its lead candidate, hNPC01, receiving clinical trial approvals from both the U.S. FDA and China's CFDA (now NMPA) for chronic stroke hemiplegia, and a recent FDA Fast Track Designation. Operating as a private, pre-revenue entity, Hopstem is positioned at the forefront of a rapidly evolving field, aiming to address a substantial unmet medical need in neuroregeneration with its scalable platform.

NeurologyCerebrovascular Disease

Technology Platform

Proprietary human induced pluripotent stem cell (iPSC) platform for differentiation into specific neural lineages, particularly forebrain neural progenitor cells (hNPCs), for scalable allogeneic cell therapy production.

Opportunities

The company addresses a massive unmet need in chronic stroke recovery with no current regenerative therapies, representing a multi-billion dollar market.

Its FDA Fast Track Designation and dual U.S./China regulatory strategy can accelerate development and provide access to two major pharmaceutical markets.

The scalable iPSC platform allows for potential expansion into other high-value neurological indications like spinal cord injury and Parkinson's disease.

Risk Factors

High clinical risk associated with novel iPSC-derived cell therapies, including potential safety issues like tumorigenicity and uncertain efficacy in complex neurological repair.

The company faces significant operational risks in scaling GMP manufacturing and navigating dual regulatory systems.

As a pre-revenue private firm, it is dependent on successive capital raises in a challenging financing environment.

Competitive Landscape

Hopstem operates in the highly competitive neuro-regenerative medicine space, facing rivals using various stem cell sources (mesenchymal, embryonic), gene therapies, and neuroprotective small molecules. It competes with other iPSC-focused biotechs (e.g., BlueRock Therapeutics, a Bayer subsidiary) and must demonstrate superior safety, efficacy, and manufacturing scalability to succeed.

More companies in Cell & Gene Therapy →More companies in United States →